ArticleCurrent neurovascular research2026
Pathogen Antibodies and Parkinson's Disease: A Two-sample Mendelian Randomization Study.
Article in Current neurovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParkinson's disease (PD) is a prototypical neurodegenerative disease. Evidence suggests infection-induced immune responses contribute to the pathogenesis of PD; however, establishing causality from observational studies remains challenging. To explore the causal relationship between pathogen-derived antibodies and PD, we conducted a two-sample Mendelian randomization (MR) analysis.
methodsGenetic variants were derived from publicly available genome-wide association study (GWAS) summary statistics, including data on 46 pathogen antibodies and PD (N = 5,861 cases). The inverse variance weighted (IVW) method served as our primary analysis. Robustness was assessed using MR-Egger, weighted median, and sensitivity analyses, including Cochran's Q test for heterogeneity and the MR-Egger intercept test for directional pleiotropy.
resultsOf the 46 pathogen antibodies tested, human herpesvirus 6 (HHV-6) p101k antibody levels demonstrated a significant association with increased PD risk (OR: 1.08, 95% CI: 1.01- 1.15, p = 0.026). Suggestive, albeit less robust evidence for potential protective associations is found involving Helicobacter pylori GroEL (OR: 0.87, 95% CI: 0.76-0.99, p = 0.041) and Merkel cell polyomavirus (MCPyV) VP1 antibodies (OR: 0.89, 95% CI: 0.79-1.00, p = 0.049). DISCUSSION: Our findings suggest potential roles for pathogen-specific immune responses in PD etiology. The association between HHV-6 p101k antibodies and PD risk may reflect virusinduced neuroinflammatory pathways, while the inverse associations observed for Helicobacter pylori GroEL and MCPyV VP1 antibodies warrant further investigation to confirm.
conclusionOur study provides genetic evidence that implicates specific pathogen antibody responses. These findings underscore the importance of investigating immune and neurovascular pathways in PD and may inform future therapeutic strategies.
Indexed as
Identifiers
41735219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.